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ABSTRACT  21 
 22 
A 10-year old crossbreed dog presented with a six-week history of hematemesis, melena, anorexia 23 
and lethargy. Clinical staging revealed a gastric mass with regional lymphadenomegaly as well as a 24 
monoclonal gammopathy manifesting as hyperglobulinemia. Cytologic and histopathologic analyses 25 
were consistent with a round cell neoplasm; neoplastic cells showed nuclear immunoreactivity for 26 
MUM1 and diffuse cytoplasmic reactivity for CD3. PCR performed on fixed and fresh tissue identified 27 
a clonal rearrangement with an IgH primer set. An extramedullary plasmacytoma (EMP) was 28 
confirmed by cellular morphology and molecular diagnostics. Following an objective response to 29 
chemotherapy the dog was euthanized 8 months after diagnosis and a post mortem examination 30 
confirmed the clinical findings. This is the first reported case of a monoclonal gammopathy 31 
secondary to a gastric EMP coupled with aberrant expression of CD3 in an aggressive plasmacytic 32 
tumor and highlights the utility of molecular diagnostics for classifying atypical hemolymphoid 33 
neoplasms. 34 
 35 
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Case Presentation 45 
 46 
A 10yr old female neutered crossbred dog presented with a 6-week history of lethargy, anorexia, 47 
vomiting with progression to hematemesis and melena. Abdominal palpation was resented but 48 
physical examination was otherwise unremarkable. Hematology showed a mild non-regenerative 49 
anemia (4.69x10¹² erythrocytes/L; reference range 5.5-8.5x10¹² erythrocytes/L). Serum biochemistry 50 
revealed hyperproteinemia (88 g/L; reference range 50-78 g/L) with hyperglobulinemia (66 g/L; 51 
reference range 28-42 g/L), hypoalbuminemia (22 g/L; reference range 29-36 g/L) and mildly 52 
elevated aspartate transaminase (73 U/L; reference range <40 U/L).  A narrow spike in the gamma 53 
region of the densitometric trace of an agarose gel serum protein electrophoretic trace was present, 54 
consistent with a monoclonal gammopathy. An extensive, circumferential mass affecting the 55 
majority of the body of the stomach and progressing into the pylorus was present on abdominal 56 
ultrasound with mural thickening and loss of normal layering. Several hypoechoic masses of variable 57 
size (ranging in diameter from 13.9 mms to 53.5 mms), surrounded by reactive hyperechoic tissue, 58 
were observed in the mesentery caudal to the stomach, consistent with mesenteric 59 
lymphadenopathy. Two left-sided lymph nodes adjacent to the left kidney were appearedalso 60 
abnormally hypoechoic and a single well-defined hypoechoic hepatic nodule (6.5 mm in diameter) 61 
was present. A small amount of free fluid cranial to the bladder was noted. Thoracic radiographs 62 
revealed an enlarged sternal lymph node. Bone marrow aspiration as part of a complete staging 63 
process revealed normal myeloid and erythroid series without neoplastic infiltrate. A working 64 
diagnosis of metastatic gastric neoplasia was reached. 65 
 66 
Fine-needle aspirates of the mesenteric lymph nodes were obtained and submitted for cytology. 67 
Modified Wright-Giemsa staining of slides revealed a pleomorphic population of round cells. Cellular 68 
margins varied along a spectrum from indistinct to well defined. Nuclei number was highly variable 69 
ranging from mono to multinucleated with moderate to large amounts of basophilic and occasionally 70 
vacuolated cytoplasm present. Some cells exhibited perinuclear halos. Chromatin was described as 71 
being clumped or coarsely reticulated. Morphology was consistent with a round cell neoplasm with 72 
plasmacytoid features (Figure 1a). As an atypical hemolymphoid malignancy was suspected 73 
iImmunocytochemistry (ICC) was performed using monoclonal antibodies raised against CD3 (1:100; 74 
Dako, Glostrup, Denmark) and CD79a (1:100; Dako, Glostrup, Denmark) antigens. Neoplastic cells 75 
exhibited dual positivity for both antigens, thus a definitive cytologic diagnosis could not be reached.  76 
 77 
Histologic evaluation of a needle-core biopsy of one of the affected mesenteric lymph nodes 78 
confirmed the presence of a malignant round cell population, obliterating normal nodal architecture.  79 
The morphology of the cells reflected the cytologic findings; mitotic figures were abnormal but 80 
mitotic rate was low (4 per 10 HPF). Very large cells were frequently observed with nuclear 81 
diameters in excess of 40 μms recorded. Marked anisocytosis and anisokaryosis were noted with 82 
numerous bi- and multinucleated cells present (Figure 1b). An immunohistochemical panel (IHC) 83 
revealed moderate neoplastic reactivity against CD79a (1:100; Dako, Glostrup, Denmark) in 20% of 84 
neoplastic cells and marked nuclear reactivity against multiple myeloma oncogene 1 (MUM1) (1:50; 85 
Dako, Glostrup, Denmark) in virtually all cells (Figure 1c). Cells also exhibited diffuse cytoplasmic 86 
reactivity against CD3 (1:100; Dako, Glostrup, Denmark) (Figure 1d) in 50% of the population and this 87 
finding was consistent when staining was repeated.  Neoplastic cells were negative for CD18 (1:20; 88 
UC Davis Leukocyte Antigen Biology Lab, Davis, CA) and Pax5 (1:100; Dako, Glostrup, Denmark). 89 
Histology was consistent with a neoplastic population of lymphoid lineage, the main differentials 90 
being a functional B cell tumor, T cell or double positive neoplasm with an associated monoclonal 91 
gammopathy.  92 
 93 
PCR was performed on fresh and formalin fixed paraffin embedded (FFPE) tumor tissue using TCRγ 94 
and IgH primer sets. with a clonal rearrangement detected with one set of the IgH primers and 95 
polyclonal products detected with the remaining IgH and TCRγ primers (Figure 2). DNA was 96 
extracted using QIAamp DNA Mini kits or DNA FFPE Tissue kits (Qiagen Ltd, Manchester, UK).  PCR 97 
was carried out using primers described by Gentilini et al 1 and Chaubert et al 2, with modifications to 98 
reaction conditions. Briefly, reactions were performed in a total volume of 25 µl, and contained 100 99 
ng DNA, each primer at 250 nM (IDT, Leuven, Belgium) and 1 x HotStarTaq Plus Master Mix (Qiagen 100 
Ltd, Manchester, UK).  Thermal cycling was carried out on a GeneAmp PCR System 9700 (Applied 101 
Biosystems, Life Technologies, Waltham, MA) using the following conditions: 95 °C for 5 minutes, 102 
followed by 40 cycles of 95 °C for 30 s, 58 °C for 30 s, 72 °C for 30 s, with a final extension of 72 °C for 103 
30 minutes. Products were visualised using GeneScan methodology on an ABI 3130xl Genetic 104 
Analyser (Applied Biosystems, Life Technologies, Waltham, MA) with a 36 cm capillary length loaded 105 
with POP-4 polymer. Appropriate electrophoretic readouts were obtained from the positive (Figure 106 
2a.) and negative (Figure 2b.) control reactions.  A clonal product of approximately 100 bases was 107 
amplified with one set of the IgH primers used (Figure 2c). With the remaining IgH and TCRγ primer 108 
sets either no product or polyclonal/ skewed polyclonal products were detected (Figures 2d, e, f, g 109 
and h).   These PCR results confirmed a tumor of B cell lineage and combined with the morphologic 110 
features and the gammopathy a secretory plasmacytoma with aberrant CD3 expression was 111 
diagnosed. 112 
 113 
Pending the PCR result, the dog was initially treated for a presumptively diagnosed anaplastic 114 
lymphoid neoplasm with one dose of L-Asparaginase (4000 IU SC) and received prednisolone at 115 
2mg/kg PO q24h. After definitive classification of the tumor as a plasmacytoma the dog was 116 
prescribed melphalan (2mg PO q48h) and the prednisolone was gradually tapered over the following 117 
month to 0.5mg/kg q48h. One month after presentation tThe hyperglobulinemia normalized to 32 118 
g/L following initiation of melphalan chemotherapy and repeat abdominal ultrasound one month 119 
after presentation revealed a marked reduction in size of both the gastric mass and associated nodes 120 
with resolution of the hepatic nodule. The gastric mass had resolved and the nodes were smaller 121 
again when ultrasound was performed at three months, however at six months progressive disease 122 
was noted ultrasonographically with tumor recurrence in the stomach and associated lymphoid 123 
tissue. Although at this time point the dog was clinically well, with normal hematology and 124 
biochemistry parameters (globulin of 36 g/L), the owners declined rescue therapy and elected for 125 
euthanasia shortly after when clinical signs recurred (over all survival time from first chemotherapy 126 
was 219 days).  127 
 128 
Post-mortem examination was performed. Gross pathology and histopathology were consistent with 129 
a metastatic plasma cell tumor involving stomach, pancreas, gastric nodes, liver, mesentery, 130 
esophagus, diaphragm and spleen. The histologic appearance of the necropsy samples was 131 
consistent with the biopsy specimen, but cellular pleomorphism and mitotic rate were increased. 132 
Post-mortem findings confirmed clinically advanced neoplasia, which explained the clinical relapse 133 
and confirmed ante-mortem diagnosis. 134 
 135 
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 139 
 140 
 141 
 142 
DISCUSSION 143 
 144 
The case reported here is a very uncommon presentation of canine stomach cancer; gGastric 145 
neoplasms are diagnosed infrequently in dogs, accounting for less than 1% of all tumors and gastric 146 
extramedullary plasmacytomas (EMPs) are rarely reported 3.  Typically EMPs are benign small 147 
solitary masses found in the skin and the oral cavity3. Gastrointestinal EMPs tend to be more 148 
aggressive with associated lymphatic metastasis 4. Monoclonal gammopathy is frequently part of the 149 
multiple myeloma (MM) clinical syndrome but is less frequently reported secondary to non-150 
cutaneous EMPs 4. Only two other cases of secretory gastrointestinal EMP have been reported in 151 
dogs, both of which were intestinal 5,6. This is the first reported case of a secretory gastric EMP. 152 
 153 
Gastrointestinal EMPs, such as the case reported here, represent a rarely encountered form of 154 
canine plasma cell pathology. Plasma cells are a terminally differentiated population of B cells that 155 
produce immunoglobulin and their malignant transformation can manifest as a spectrum of 156 
different neoplastic entities.   Both multiple myeloma and IgM (Waldenstom’s) macroglobulinemia 157 
are reported in dogs as systemic disease syndromes with bone marrow infiltration critical for 158 
diagnosis 7. Alternatively solitary plasmacytomas can occur either intraosseously or in an 159 
extremedullary form (EMP) 4. Gastrointestinal EMPs are infrequently reported in dogs but generally 160 
behave in aggressive manner with frequent nodal metastasis 4,7. Only one previous report of a 161 
gastric plasmacytoma with nodal metastasis exists in a dog, however it was non-secretory8. The case 162 
reported here is a unique presentation of a gastric EMP with distant metastasis and an associated 163 
monoclonal gammopathy.   164 
 165 
Diagnosis of this gastric neoplasm was partly facilitated by the application of panels ofVarious 166 
immuno-cytologic and/ -histologic cellular markers are available with the aim ofto  identifyingaid 167 
with hematopoietic cell lineage identification. of hematopoietic malignancies. For canine plasmacytic 168 
tumors, multiple myeloma oncogene 1/ interferon regulatory factor 4 (MUM1/IRF4) is a 169 
transcription factor with a key role in plasma cell production, which is a specific and sensitive 170 
immunohistochemical marker 9. A second transcription factor, Pax5, is involved in B cell 171 
development and acts as a useful immunohistochemical marker for identifying canine B cell 172 
lymphoma but is absent in differentiated plasma cells 10. The expression of the cell surface markers 173 
CD79a (a B cell receptor signaling component) and CD18 (a leukocyte adhesion molecule subunit) 174 
are detected variably using antibodies for immunohistochemistry in canine plasma cell neoplasia 9. 175 
Cell membrane staining for CD3, a signaling protein associated with the T cell receptor, has been 176 
used to identify canine T cells for over 20 years 11 and has been documented in aggressive human 177 
plasma cell tumors as an exceedingly rare occurrence 12. Interestingly a 67-year-old male patient 178 
previously diagnosed with multiple myeloma subsequently developed gastrointestinal bleeding with 179 
clinical investigation revealing the presence of CD3 positive neoplastic plasma cells within the 180 
stomach, however any possible relationship between CD3 positive plasma cells and gastrointestinal 181 
localization would be highly speculative given the rarity of such pathology in both species 12.   In a 182 
case series classifying lymphoid malignancies in the dog and cat by the WHO system, two indolent 183 
cases of canine plasmacytoma were reported as positive for both CD3 and CD79a, however no 184 
additional information was given and diagnosis was based solely on histopathologic morphology 13.  185 
Understanding the physiologic roles of marker molecules and appreciating the limitations of 186 
immunophenotypic markers assisted with the definitive diagnosis of EMP in this case.   187 
 188 
The final diagnosis of EMP with aberrant immunophenotypic features was reached using a 189 
combination of clinicopathologic and molecular tests, namely histopathologic and cytologic 190 
morphology alongside a monoclonal gammopathy and notably a clonal IgH rearrangement. Co-191 
expression of T cell (e.g. CD3) and B cell lineage (e.g. CD79a) markers can be an aberrant finding and 192 
at times confound the diagnosis of lymphoid neoplasms in dogs 7., As documented in this case, 193 
monoclonal gammopathies are usually associated with B-cell neoplasmsand although rare,, 194 
howeveralthough in human oncology monoclonal gammopathymonoclonal gammopathies 195 
secondary to T cell neoplasms have has also been reported;, in human oncology but this has not 196 
been observeddocumented in dogs, however14,15. In cases of hemolymphoid malignancy which have 197 
ambiguous results, PCR for clonality of antigen receptor rearrangements is usually considered the 198 
diagnostic method of choice 16, as proved to be the case for the EMP reported here.  Additional 199 
diagnostic confirmation was demonstrated by shrinkage of the mass in response to the appropriate 200 
treatment for an aggressive plasma cell neoplasm, achieving an objective, albeit short-lived clinical 201 
response with excellent quality of life. The case reported here not only documents for the first time, 202 
aberrant CD3 expression in an aggressive canine gastric EMP with monoclonal gammopathy but also 203 
emphasizes the role of molecular diagnostics in ensuring appropriate therapeutics for veterinary 204 
patients. 205 
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 259 
FIGURE LEGENDS 260 
 261 
Figure 1: Cytologic and histologic images from a mesenteric lymph node. 262 
1a: Cytologic smear of fine needle aspirate taken from a mesenteric lymph node and stained with 263 
modified Wright-Giemsa revealing a pleomorphic population of malignant round cells with 264 
erythrocytes and neutrophils noted in the background (x40 objective lens). 265 
1b: Needle-core biopsy taken from a mesenteric lymph node and stained with haematoxylin and 266 
eosin showing the same population of malignant round cells obliterating normal nodal architecture 267 
(x10 objective lens). 268 
1c: Immunohistochemical staining of a needle-core biopsy taken from a mesenteric lymph node 269 
revealing marked nuclear reactivity against MUM1 (x20 objective lens). 270 
1d:  Immunohistochemical staining of a needle-core biopsy taken from a mesenteric lymph node 271 
revealing diffuse cytoplasmic reactivity against CD3 (x20 objective lens). 272 
 273 
Figure 2: PCR electrophoretograms from fresh mediastinal lymph node aspirate sample. 274 
Approximate product size in bases (b) is indicated at the top of each plot. Amplification products are 275 
in blue or green; size markers are in red.  276 
2a: Positive DNA amplification controls in green (Cμ; approx. 128 b) and blue (γ-actin; approx. 272 b). 277 
2b: No template control. No amplification within the expected size range is seen.  278 
2c: Clonal product of approx. 100 b amplified using an immunoglobulin heavy chain (IgH) primer set. 279 
A clonal product of the same length was amplified from FFPE material from this site using the same 280 
primer set, and also from post-mortem material from mediastinal lymph node and stomach mass.  281 
2d,e,f: Polyclonal or skewed polyclonal products are amplified using T-cell receptor gamma primer 282 
sets.  283 
2g,h: Polyclonal or poor amplification is noted with a further four IgH primer sets. 284 
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